Loading…
Loading…
The Law Offices of Frank R. Cruz announces an investigation of MiMedx Group, Inc. (“MiMedx” or the “Company”) MDXG on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On December 29, 2023, after the market closed, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company’s placental-derived tissue product, Axiofill, does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product.
On this news, MiMedx’s stock price fell $0.90, or 10.3%, to close at $7.87 per share on January 2, 2023, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased MiMedx securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111560155/en/
Loading…
Loading…
